In 2020, Sue volunteered for a study at the Washington University School of Medicine in St. Louis. Researchers there were ...
The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...
Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.
MedPage Today on MSN12dOpinion
How a Book Is Undermining Progress Against Alzheimer'sSystematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the ...
In 2020, Sue volunteered for a study at the Washington University School of Medicine in St. Louis. Researchers there were conducting part of a nationwide clinical trial of Leqembi, then known by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback